A complete response at 30 months may be a surrogate for no survival detriment in some patients with follicular lymphoma treated with a first-line rituximab-based regimen.
FORTIS, a phase 3 randomized study, evaluated the effects of dose intensity of the frontline fludarabine/cyclophosphamide/rituximab on progression-free and overall survival in adult patients with CLL.
Older age is associated with worse prognosis in patients with early-stage Burkitt lymphoma, according to study authors.
A qualitative study revealed the unique needs of lymphoma survivors transitioning from active care to survivorship.
Survey results reveal the effects of cancer treatment on job-related mental and physical abilities in survivors who were AYAs at diagnosis.
A patient case illustrates the need for high suspicion of GI perforation and patient education on symptoms of potential adverse effects in certain patients with gastrointestinal lymphoma.
Using a gene expression-based identifier, researchers found a method for discerning patients with DLBCL who may benefit from nonstandard therapies.
Two simultaneous studies demonstrate improved progression-free survival and overall survival in patients with uMCL who receive induction therapy with RB/RC followed by ASCT.
Checkpoint-based therapies may sensitize patients to subsequent therapies.
[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.
